Ethambutol
- Generic Name
- Ethambutol
- Brand Names
- Etibi, Myambutol
- Drug Type
- Small Molecule
- Chemical Formula
- C10H24N2O2
- CAS Number
- 74-55-5
- Unique Ingredient Identifier
- 8G167061QZ
- Background
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis.
Ethambutol was granted FDA approval on 6 November 1967.
- Indication
Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Ethambutol is commonly used in combination with isoniazid, rifampin, and pyrazinamide.
- Associated Conditions
- Mycobacterium Avium Intracellulare Complex (MAC), Mycobacterium Infections, Pulmonary Tuberculosis (TB)
Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
- Conditions
- HIVTuberculosis
- Interventions
- Dietary Supplement: Pyridoxine (vitamin B6)
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 104
- Registration Number
- NCT04311502
- Locations
- 🇭🇹
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti
🇿🇼Milton Park CRS, Harare, Zimbabwe
🇿🇦CAPRISA eThekwini CRS, Durban, Kwa Zulu Natal, South Africa
Efficacy and Safety of Intravenous Treatment of Tuberculosis
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Yuria-Pharm
- Target Recruit Count
- 166
- Registration Number
- NCT04150367
- Locations
- 🇺🇦
Regional Antituberculosis Dispensary, Kherson, Ukraine
🇺🇦Regional Clinical Antituberculosis Dispensary, Sumy, Ukraine
🇺🇦Regional phthisiopulmonary center, Ivano-Frankivs'k, Ukraine
Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)
- Conditions
- Uveitis, Anterior
- Interventions
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 116
- Registration Number
- NCT04117698
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
- Conditions
- TuberculosisPre-XDR-TBExtensively Drug-Resistant TuberculosisMulti Drug Resistant TuberculosisRifampicin Resistant Tuberculosis
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Wits Health Consortium (Pty) Ltd
- Target Recruit Count
- 402
- Registration Number
- NCT04062201
- Locations
- 🇿🇦
Jose Pearson TB Hospital, Port Elizabeth, Eastern Cape, South Africa
🇿🇦King DinuZulu Hospital Complex, Durban, KwaZulu Natal, South Africa
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
- Conditions
- Nontuberculous Mycobacterium InfectionMycobacterium Avium Complex
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Kevin Winthrop
- Target Recruit Count
- 474
- Registration Number
- NCT03672630
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸University of California, San Diego, San Diego, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University College, London
- Target Recruit Count
- 675
- Registration Number
- NCT03474198
- Locations
- 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬Infectious Diseases Institute, Kampala, Uganda
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
- Conditions
- Lung InfectionMycobacterium Avium Complex
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 424
- Registration Number
- NCT03236987
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷CHU Amiens Picardie, Amiens, Picardie, France
🇫🇷Saint Joseph Hospital, Marseille, France
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 3900
- Registration Number
- NCT02901288
- Locations
- 🇨🇳
The Infectious Hospital of Hebi, Hebi, Henan, China
🇨🇳Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- St George's, University of London
- Target Recruit Count
- 672
- Registration Number
- NCT02581527
- Locations
- 🇺🇬
Epicentre, Mbarara, Uganda
🇵🇪Hospital Nacional Dos de Mayo, Lima, Peru
🇳🇵GENETUP, National Anti-TB Association, Kathmandu, Nepal
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
- Conditions
- Tuberculosis
- Interventions
- Dietary Supplement: Pyridoxine
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 60
- Registration Number
- NCT02563327
- Locations
- 🇺🇬
Mulago Hospital, Kampala, Uganda
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.